New vaccine combo shows promise for hard-to-treat melanoma
NCT ID NCT04526899
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a combination of an experimental cancer vaccine (BNT111) and an immunotherapy drug (cemiplimab) in 184 adults with advanced melanoma that no longer responded to standard immunotherapy. Participants were randomly assigned to receive the combination or either treatment alone. The main goal was to see how many patients' tumors shrank or disappeared. This study is for people with stage III or IV melanoma that cannot be surgically removed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AOU Citta della Salute e della Scienza di Torino
Turin, 10126, Italy
-
Atlantic Health System / Morristown Medical Center
Morristown, New Jersey, 07962, United States
-
Azienda ospedaliera universitaria Bologna
Bologna, 40138, Italy
-
Beatson West of Scotland Cancer Centre - Greater Glasgow Health Board
Glasgow, G12 0YN, United Kingdom
-
Border Medical Oncology
East Albury, 2640, Australia
-
Complejo Hospitalario Universitario De Santiago De Compostela
Santiago de Compostela, 15706, Spain
-
Fondazione del Piemonte per l'Oncologia, Istituto di Candiolo (IRCCs)
Candiolo, 10060, Italy
-
Gold Coast Hospital
Southport, 4215, Australia
-
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
-
Hospital De La Santa Creu I Sant Pau
Barcelona, 08041, Spain
-
Hospital General Universitario Gregorio Maranon
Madrid, 28007, Spain
-
Hospital Teresa Herrera (CHUAC)
A Coruña, 15009, Spain
-
Hospital Universitari Germans Trias i Pujol (HUGTP)
Badalona, 8916, Spain
-
Hospital Universitario Marques De Valdecilla
Santander, 39008, Spain
-
Hospital Universitario Puerta de Hierro - Majadahonda
Madrid, 28222, Spain
-
Hospital Universitario Virgen de la Arrixaca
El Palmar, 30120, Spain
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
IOV - Istituto Oncologico Veneto - IRCCS
Padova, 35128, Italy
-
Inova Dwight and Martha Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Institut Català d'Oncologia l'Hospitalet
Barcelona, 08907, Spain
-
Istituto Di Ricovero E Cura A Carattere Scientifico - Istituto Tumori Giovanni Paolo Ii
Bari, 70124, Italy
-
Istituto Nazionale Tumori Fondazione Pascale - IRCCS · S.C. Oncologia Medica Melanoma, Immunoterapia Oncologica e Terapie Innovative
Naples, 80131, Italy
-
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumpori (IRST)
Meldola, 47014, Italy
-
Klinik für Dermatologie, Dermatochirurgie, Allergologie, Klinikum Bremen-Ost, Gesundheitnord GmbH
Bremen, 28325, Germany
-
Klinikum Nürnberg Nord
Nuremberg, 90419, Germany
-
Klinikum der Julius-Maximilians-Universität Würzburg
Würzburg, 97080, Germany
-
MD Anderson Cancer Center
Madrid, 28033, Spain
-
Melanoma Institute Australia
Sydney, 2060, Australia
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Warsaw, 02-781, Poland
-
Oncology Hematology West P.C. dba Nebraska Cancer Specialists
Omaha, Nebraska, 68310, United States
-
Policlinico Universitario Campus Bio-Medico
Rome, 00128, Italy
-
Royal Cornwall Hospital
Truro, TR1 3LJ, United Kingdom
-
Sylvester Comprehensive Cancer Center/ UMHC
Miami, Florida, 33136, United States
-
Szpital Specjalistyczny im. Luwika Rydygiera w Krakowie Sp. z o.o.
Krakow, 31-826, Poland
-
The Christie - The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
Universita di Siena -Azienda Ospedaliera Universitaria Senese-Policlincio Santa Maria Alle Scotte
Siena, 53100, Italy
-
Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur)
Valencia, 46026, Spain
-
University Hospital Tübingen
Tübingen, 72076, Germany
-
University Of Arizona College Of Medicine
Tucson, Arizona, 85724, United States
-
University of California, San Francisco: Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158-3214, United States
-
Universitätsklinikum Essen (AoR)
Essen, 45147, Germany
-
Universitätsklinikum Freiburg, Klinik füer Dermatologie und Venerologie
Freiburg im Breisgau, 79104, Germany
-
Universitätsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Universitätsklinikum Leipzig
Leipzig, 04103, Germany
-
Universitätsklinikum Mannheim GmbH
Mannheim, 68167, Germany
-
Universitätsklinikum Schleswig-Holstein (UKSH), Campus Kiel Hautkrebszentrum Kiel
Kiel, 24105, Germany
-
Universitätsmedizin der Johannes Gutenberg Universität Mainz KoeR
Mainz, 55131, Germany
-
Uniwersyteckie Centrum Kliniczne
Gdansk, 80214, Poland
-
Zachodniopomorskie Centrum Onkologii
Szczecin, 71-730, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- Can interferon keep melanoma from coming back after surgery?
- Gene-Hacked immune cells take on tough cancers
- Pee power: urine bacteria may predict melanoma treatment success
- Engineered immune cells take on Hard-to-Treat melanoma